The 340B program was created with good intentions to help vulnerable and underserved patients access care, but unfortunately, it has evolved into a massive, poorly supervised program with weak transparency and accountability safeguards.
Discussing the 340B Drug Pricing Program and healthcare fraud.
Share
More from Diana Harshbarger
I have an amendment at the desk. The Acting CHAIR. The Clerk will designate the amendment. The text of the amendment is as follows: At the end of the bill (before the spending reduction account), insert the following: Sec. ___. None of the…
Congress should bring transparency, competition, and accountability to this process so providers, innovators, and patients all benefit from a more open and competitive system.
As a lifelong pharmacist, I’ve seen firsthand how PBMs game the system. When the same corporate giant that sets reimbursement rates also owns the pharmacy collecting them, that’s not a free market—it’s a rigged one.
I have a question as to why we even have a gender policy council when that authority should fall under the Department of Health and Human Services under Secretary Becerra. I think it is a redundancy that we do not need. Mr. Chairman, I…
Other voices in this conversation
